Edwin Reisz Sells 42,057 Shares of Aveanna Healthcare (NASDAQ:AVAH) Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) insider Edwin Reisz sold 42,057 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $7.65, for a total transaction of $321,736.05. Following the completion of the sale, the insider directly owned 1,567,043 shares in the company, valued at approximately $11,987,878.95. The trade was a 2.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Aveanna Healthcare Stock Performance

Shares of AVAH opened at $7.34 on Friday. Aveanna Healthcare Holdings Inc. has a 12-month low of $3.67 and a 12-month high of $10.32. The stock has a market cap of $1.53 billion, a P/E ratio of 20.39 and a beta of 2.06. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 140.39. The company has a 50-day moving average of $8.45 and a two-hundred day moving average of $8.46.

Analyst Ratings Changes

A number of research firms recently issued reports on AVAH. Truist Financial upped their target price on Aveanna Healthcare from $9.50 to $10.00 and gave the company a “hold” rating in a research note on Friday, November 7th. Raymond James Financial restated an “outperform” rating and issued a $13.00 price objective on shares of Aveanna Healthcare in a research report on Friday, December 5th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Monday, December 29th. Royal Bank Of Canada upped their target price on shares of Aveanna Healthcare from $10.00 to $11.00 and gave the company a “sector perform” rating in a report on Thursday, January 15th. Finally, UBS Group raised their price target on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “neutral” rating in a research note on Thursday, January 15th. Five equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $11.06.

Hedge Funds Weigh In On Aveanna Healthcare

Large investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new stake in Aveanna Healthcare in the 2nd quarter valued at about $43,000. MQS Management LLC acquired a new stake in shares of Aveanna Healthcare in the second quarter worth approximately $59,000. Belvedere Trading LLC purchased a new stake in Aveanna Healthcare in the second quarter valued at approximately $62,000. Oxford Asset Management LLP acquired a new position in Aveanna Healthcare during the second quarter worth approximately $64,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Aveanna Healthcare during the second quarter worth approximately $68,000. 87.96% of the stock is currently owned by hedge funds and other institutional investors.

Key Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Institutional buying in recent quarters — firms including Invesco, Millennium, Zimmer Partners and others increased or established positions in Q4, a vote of confidence that can support the stock over the medium term. MarketBeat Institutional Activity
• Positive Sentiment: Despite recent sales, insiders still retain large, multi‑million‑dollar stakes (CEO, CFO and others remain major shareholders), which can temper panic selling and signal some continued alignment with shareholders. SEC Filing
• Neutral Sentiment: Reported short interest shows zero shares for mid‑February — this is almost certainly a reporting/data anomaly and does not indicate genuine lack of short interest. Treat the short‑interest figure cautiously. Short Interest Data
• Neutral Sentiment: Trading volume today was below recent averages; low volume can amplify price moves when large blocks or news hit the tape (higher intraday volatility risk).
• Neutral Sentiment: Analyst coverage remains mixed: consensus is around a “Hold” with an average target near $11 — helpful context for longer‑term positioning but not an immediate catalyst. Analyst Summary
• Negative Sentiment: Large, concentrated insider selling Feb. 17–19 by CEO Jeff Shaner — roughly 461,900 shares sold across three days (~$3.4M reported proceeds) — is the primary negative catalyst driving downward pressure as the market interprets sizeable CEO disposals as risk reduction. CEO Sales SEC Filing
• Negative Sentiment: Additional senior/executive selling (CFO Matthew Buckhalter, CAO Deborah Stewart, and other insiders including Edwin C. Reisz and Patrick A. Cunningham) involved hundreds of thousands of shares total across the same dates — a reinforcing negative signal that likely amplified the pullback. Other Insider Filings
• Negative Sentiment: Independent coverage singled out the insider selling as the main reason for a recent ~5–6% pullback, increasing market attention on the disposals and reinforcing short‑term selling pressure. AAII Article

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.